About My Health Careers Internship MedBlogs Contact us

Study Offers Hope for Potential Disease-modifying Drug for Osteoarthritis

by VR Sreeraman on July 30, 2007 at 8:01 PM
Font : A-A+

Study Offers Hope for Potential Disease-modifying Drug for Osteoarthritis

A new study has shown promise for the development of a disease-modifying drug for osteoarthritis.

The study has raised hopes for developing bone-building calcitonin for protecting post-menopausal women against cartilage degradation and joint destruction.


The world's most common joint disease, osteoarthritis (OA) affects more than 10 percent of American adults, nearly 80 percent of people past age 55, and about three times as many women as men. Treatment has been targeted at controlling the pain that tends to come with the progressive loss of articular cartilage cushioning the joints, disintegration of the underlying bone, and the formation of bone spurs or osteophytes. No drug has been proven to block OA's specific joint-destroying processes so far.

Calcitonin, an amino acid hormone produced by the thyroid gland, has been shown to reduce bone breakdown and increase bone density. Typically prescribed as a nasal spray, it is widely used in the treatment of Paget's disease and osteoporosis.

Whether this drug can also counteract the cartilage damage characteristic of OA remains unknown. Yet, based on the results of a recent study on female rats, featured in the August 2007 issue of Arthritis & Rheumatism, oral calcitonin may successfully protect postmenopausal women from the ongoing pain and eventual disability of joint destruction.

Conducted by a team of researchers in Denmark, this study focused on ovariectomized rats, a model that closely resembles the changes in the human skeletal system during menopause. Fifty female Sprague-Dawley rats were divided, randomly and equally, into 5 study groups: ovariectomy; ovariectomy, plus 60-day release estrogen pellet inserted; ovariectomy, plus 2.0 mg/kg of salmon calcitonin and 50 mg/kg of 5CNAC, a carrier; ovariectomy, plus 50 mg/kg of 5CNAC; and sham operation.

Each rat's body weight was recorded at regular intervals. After 9 weeks, the rats were euthanized. Then, researchers assessed each blood sample for increases in C-telopeptide type II collagen (CTX-II), shown to correlate with degradation of articular cartilage in rats; microscopically examined and blindly scored a section of every rat's knee joint for surface erosions of cartilage; and performed statistical analyses of the data.

Compared with the sham-operated group, all the ovariectomized rats experienced a noticeable boost in levels of CTX-II for the first 6 weeks, indicating accelerated articular cartilage degradation.

During the 9-week trial, estrogen therapy effectively worked to offset this increase to levels lower than the carrier and non-treated groups, whose levels were not significantly different. However, calcitonin worked better, bringing levels to below those even in the sham-operated group.

Similarly, estrogen and calcitonin both provided significant protection against surface erosions of knee joint cartilage. Again, calcitonin worked better, preventing erosions completely. Of note, the rats that had estrogen therapy gained the least weight of all the ovariectomized rats, effectively easing the erosive toll on the weight-bearing knee joints. Interestingly, calcitonin had no positive impact on body weight, yet protected against the erosions linked to joint destruction in OA.

"Calcitonin treatment may counter the acceleration of cartilage degradation and the related rise of surface erosions indicating important chondroprotective properties of this drug which need to be explored in upcoming clinical trials," concludes the study's lead author, Bodil-Cecilie Sondergaard.

Stephen Honig, MD, New York University School of Medicine and Hospital for Joint Diseases says, "The recognition, enhanced by the report of Sondergaard and colleagues, that antiresorptive agents may target abnormalities of both cartilage and bone represents a significant advance in our understanding of the OA disease process and could lead to new disease-modifying treatments in the near future."

Source: ANI

News A-Z
News Category
What's New on Medindia
Memory Loss - Can it be Recovered?
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Osteoarthritis Signature Drug Toxicity 

Recommended Reading
Osteoarthritis is one of the commonest joint disorder and occurs as we age due to wear and tear of ....
Post Menopausal Women are Prone to Gum Disease
University at Buffalo epidemiologists has provided new information on the prevalence of certain ......
Roche’s Arthritis Drug Successful in III Stage Trail
Roche Holding AG says that arthritis drug Actemra has proved successful in a phase III clinical ......
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use